TC Patent Investigation Moving Forward; Info Requests Expected By Spring
The Federal Trade Commission's formal inquiry into patent settlements between brand and generic companies could kick off during the spring, Bureau of Competition Assistant Director Richard Feinstein told a Health Industry Group Purchasing Association conference in Las Vegas Feb. 9.
You may also be interested in...
Mylan has to give the Federal Trade Commission 30-day advance notice for any exclusive agreements dealing with active pharmaceutical ingredients under a Nov. 29 consent decree.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials